William Thompson
Internal Medicine · Newport Beach, CANPI 1174588891
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 635 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Gilead at 25.0% of the total. Reporting peaked in 2022 at $3,139 and has fallen 95.8% since, to $133 in 2024. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 635 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- Viiv Healthcare Company$2K
- AbbVie$1K
- Johnson & Johnson$1K
- EMD Serono, Inc.$815
- Insmed, Inc.$585
- plus $4K from 28 others
What the payments were for
- Speaking & faculty fees$1721%
- Food & beverage$12,11697%
- Education$1922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 162 | $3,126 |
| Viiv Healthcare Company | 104 | $1,937 |
| AbbVie(2 entities) | 64 | $1,353 |
| Johnson & Johnson(2 entities) | 61 | $1,114 |
| EMD Serono, Inc. | 40 | $815 |
| Insmed, Inc. | 29 | $585 |
| Theratechnologies Inc. | 24 | $520 |
| Amgen | 21 | $472 |
| Melinta Therapeutics, LLC | 19 | $267 |
| Amarin Pharma, Inc. | 10 | $215 |
| Paratek Pharmaceuticals, Inc. | 8 | $178 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $176 |
| Shionogi Inc | 8 | $174 |
| Napo Pharmaceuticals Inc | 10 | $172 |
| Astellas Pharma US Inc | 8 | $164 |
| Antares Pharma, Inc. | 9 | $142 |
| Smith+Nephew | 6 | $121 |
| Abiomed | 2 | $119 |
| Philips North America LLC | 5 | $102 |
| Tetraphase Pharmaceuticals, Inc. | 4 | $100 |
| Tactile Systems Technology Inc | 6 | $94 |
| Vyera Pharmaceuticals, LLC | 4 | $80 |
| Pfizer | 3 | $79 |
| Eisai Inc. | 3 | $66 |
| Ferring Pharmaceuticals Inc. | 2 | $66 |
| Exact Sciences | 4 | $63 |
| Lilly USA, LLC | 2 | $46 |
| Ascend Therapeutics US, LLC | 2 | $25 |
| CSL Behring | 1 | $25 |
| Aytu Biopharma, Inc. | 1 | $24 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $11 |
How this compares
$12,481 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JulucaDolutegravir/Rilpivirine | 30 | $111,092 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 23 | $103,470 |
| Rosuvastatin Calcium | 12 | $230 |
| Atorvastatin Calcium | 21 | $135 |
| Alendronate Sodium | 12 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyJuluca | $1,937 | $111,09230 claims |
| GileadBiktarvy | $3,126 | $103,47023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Newport Beach
- Tung NgoNewport Beach$4.9M
- Andrew ChengSouth San Francisco$55.1M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.